BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit

In This Article:

DPX Formulations Superior to Mixing with Commonly Used Adjuvants

DPX Without Antigen Cargo Has Immune Stimulating Properties

Unique Potential for DPX in New Fields of Use

VANCOUVER, BC, Dec. 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or prevent tumor growth following tumor challenges. DPX formulations were more effective than mixing with commonly used adjuvants, and DPX formulations were demonstrated to be as effective as the gold standard, bone marrow-derived dendritic cells. A highly significant result of the study is DPX formulations (with a checkpoint inhibitor) without a packaged cargo peptide appear to have meaningful immune stimulating properties on their own.

BioVaxys Technology Corp. Logo
BioVaxys Technology Corp. Logo

BioVaxys' DPX™ technology ("DPX") is a patented delivery platform that can incorporate a range of bioactive molecules, such as mRNA/polynucleotides, peptides/proteins, virus-like particles, and small molecules, to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform, which is non-aqueous and non-systemic, facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease.

David Berd, MD, Chief Medical Officer of BioVaxys, delivered the keynote presentation entitled "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies" based on studies of tumor neopeptides conducted by Hakimeh Ebrahimi-Nik, DVM, PhD, of The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, where her team studies the molecular mechanisms that enhance immune responses against tumors.

Dr. Nik's study utilized the Meth A mouse tumor model, a widely used experimental model in cancer research. Novel, tumor-specific peptides (neopeptides) were identified and biomanufactured using standard molecular techniques. Several peptides served as effective vaccines when injected with bone marrow-derived dendritic cells. Administration of these vaccines prior to a challenge with live Meth A sarcoma cells completely or partially prevented tumor growth, while vaccines composed of non-protective peptides did not. Dr. Nik then tested the immunoprotective properties of DPX formulations, made by incorporating a rejection peptide, Neo1, into the DPX formulation. To make the vaccine more potent the drug 9D9---a checkpoint inhibitor---was administered with the vaccine. DPX-Neo1 plus 9D9 was found to be as effective in preventing tumor growth as the standard Neo1 + dendritic cells vaccine.